Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of NASDAQ:BLPH opened at $0.04 on Monday. Bellerophon Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.10. The firm’s 50-day moving average is $0.04 and its 200 day moving average is $0.04. The company has a market capitalization of $489,200.00, a price-to-earnings ratio of -0.05 and a beta of 0.71.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.